TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03860857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing
Description: A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing
Description: A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing
Description: A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing
Description: A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing
Description: A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing
Description: A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.
Study: NCT01050582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: As per local prescribing practices

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other atypical antipsychotic drugs
Description: As per local prescribing practices
Study: NCT04353713

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40% Dextrose Gel
Description: Prophylactic administration of 40% dextrose gel via buccal mucosa to prevent newborn hypoglycemia
Study: NCT03860857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing
Description: A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing
Description: A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing
Description: A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.
Study: NCT01655992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 2500mg／m2／day divided into twice two weeks on one week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1 generic
Description: 40mg／m2 bid four weeks on two weeks off
Study: NCT03279172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct laryngoscope
Description: procedure entubatıon

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct laryngoscope
Description: procedure entubatıon

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: videolaryngoscope

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: videolaryngoscope
Study: NCT04353713

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 2% carboxymethylcellulose gel
Description: placebo
Study: NCT01826513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard AutoSet algorithm
Description: An AutoSet device with a standard algorithm developed for sleep breathing parameters that are specific to a particular gender.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard AutoSet algorithm
Description: An AutoSet device with a standard algorithm developed for sleep breathing parameters that are specific to a particular gender.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified AutoSet algorithm
Description: An AutoSet device with an algorithm developed for sleep breathing parameters specific to females.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified AutoSet algorithm
Description: An AutoSet device with an algorithm developed for sleep breathing parameters specific to females.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified AutoSet algorithm
Description: An AutoSet device with an algorithm developed for sleep breathing parameters specific to females.
Study: NCT04593615

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG near-infrared imaging
Description: Indocyanine green tracer is used to guide laparoscopic D2 lymph node dissection for gastric cancer

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ICG near-infrared imaging
Description: Indocyanine green tracer is used to guide laparoscopic D2 lymph node dissection for gastric cancer
Study: NCT03267524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive Walking for Recovery from Surgery prehabilitation intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT02142803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study: NCT02913443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7051790
Description: RO7051790 will be given orally. Treatment will be continued until disease progression/treatment failure, unacceptable toxicity, or study discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7051790
Description: RO7051790 will be given orally. Treatment will be continued until disease progression/treatment failure, unacceptable toxicity, or study discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7051790
Description: RO7051790 will be given orally. Treatment will be continued until disease progression/treatment failure, unacceptable toxicity, or study discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7051790
Description: RO7051790 will be given orally. Treatment will be continued until disease progression/treatment failure, unacceptable toxicity, or study discontinuation.
Study: NCT00952835

Intervention type: OTHER
Intervention: regular treatment
Description: regular treatment
Study: NCT02142803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study: NCT00297752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceriumnitrate silversulfadiazine (flammacerium)
Description: treatment of patients with facial burns with CE-SSD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: silversulfadiazine (flammazine)
Description: treatment of patients with facial burns with SSD
Study: NCT00168025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulins Intravenous (Human)
Study: NCT05530135

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Exercise program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural therapy
Description: Cognitive behavioural therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinical care
Description: Standard clinical care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard clinical care
Description: Standard clinical care
Study: NCT03258983

Intervention type: OTHER
Intervention: Alpha-linolenic acid
Description: Exposure to dietary intake of alpha-linolenic acid (ALA) will be assessed using a detailed food frequency questionaire filled in by participants included in the Diet, Cancer and Health cohort at baseline. Exposure to adipose tissue content of ALA will be determined by gas chromatography in all incident cases and in subcohort of 3500 participants randomly drawn from the total cohort.
Study: NCT01951105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Take one 250mg naproxen tablet three times a day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Description: Take one 250mg naproxen tablet three times a day for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa/Levodopa
Description: 12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has responded, the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take two placebo capsules three times a day for 12 weeks.
Study: NCT03234842

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy
Description: 59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon Radiation Therapy
Description: 59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
Study: NCT05530135

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinical care
Description: Standard clinical care
Study: NCT03234842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Concurrent weekly chemotherapy at standard doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Concurrent weekly chemotherapy at standard doses
Study: NCT01955720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655075
Study: NCT00815542

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double balloon catheter
Description: cervical ripening using double balloon catheter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prostaglandins E2
Description: prostaglandins E2 - Intravaginal Propess for 24 hours
Study: NCT00945724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate
Description: Weeks 1-15:~* 6 cycles of CHOP on Days 1 to 5, to be repeated q21 Days~* Rituximab 375 mg/m2 on Day 0 or Day 1 of every CHOP cycle~* IT chemoth:Depocyte 50 mg on Day 0 of cycles 2,3,4\&5 of R-CHOP~Weeks 18-22:~• Methotrexate 1.5 g/m2 q14 Days x 2~From Week 24:~• Scrotal prophylactic radiotherapy or involved field radiotherapy(but can be planned concomitantly to R-CHOP in pts with bilateral disease)
Study: NCT03887442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
Study: NCT00395707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: 0.3mg/0.05 ml or 0.5mg/0.05 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: 0.3mg/0.05 ml or 0.5mg/0.05 ml
Study: NCT01118208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blister packaging medications
Description: Dispensing prescription medications on pre-filled blister package cards.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dispense as usual
Description: Dispensing prescription medications in standard pill bottles.
Study: NCT03690505

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interviews
Description: informant-based questionnaire semi-structured individual interviews focus group interviews
Study: NCT01990950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® Fenestrated AAA Endovascular Graft
Description: The Zenith® Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneursyms having morphology suitable for endovascular repair
Study: NCT02856464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism)

Intervention type: OTHER
Group type: OTHER
Intervention: DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice
Study: NCT00205569

Intervention type: BEHAVIORAL
Intervention: First Steps Educational Curriculum
Description: 10 sessions with the research participant to review an educational curriculum regarding brain injury rehabilitation and community reintegration
Study: NCT01681589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulator (TDCS)
Description: Group will receive active TDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: This group will receive Sham TDCS

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Control Group
Description: Healthy Controls will be involved in the Study. Healthy Controls will receive no Intervention. There will be 1 screening visit and 1 testing visits.
Study: NCT02298192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.
Study: NCT03887442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + Paclitaxel
Description: Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
Study: NCT02647190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinia Chrysanthemi asparaginase
Study: NCT00357799

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VeinViewer
Description: Using the VeinViewer, IV attempts will be made
Study: NCT03773029

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: soy isoflavone
Description: 100 mg soy isoflavone (as 2 capsules)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 capsules of placebo
Study: NCT03524040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEB-250
Description: Gold microparticles (SEB-250) are massaged into 2 or 3 2x2 cm facial areas and exposed to 2 pulses from a diode laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEB-250
Description: Gold microparticles (SEB-250) are massaged into 2 or 3 2x2 cm facial areas and exposed to 2 pulses from a diode laser
Study: NCT06447857

Intervention type: OTHER
Intervention: Cardiac MRI
Description: This retrospective study included patients diagnosed with STEMI at the Affiliated Hospital of Xuzhou Medical University. All patients underwent CMR.
Study: NCT01692535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: Intubation with one of the six videolaryngoscopes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: Intubation with one of the six videolaryngoscopes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: Intubation with one of the six videolaryngoscopes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: Intubation with one of the six videolaryngoscopes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: Intubation with one of the six videolaryngoscopes
Study: NCT02948660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate Tablets
Description: All participants were administered 10 mg of zolpidem tartrate tablets either via a feeding tube (for patients with prolonged disorders of consciousness) or orally.
Study: NCT01692535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: Intubation with one of the six videolaryngoscopes
Study: NCT02732925

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 Balloon Kyphoplasty
Description: Arm 2 Balloon Kyphoplasty (Medtronic LCC) and Conservative Treatment~Subjects will be blinded and randomised to Arm 2 and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.~Below is a list of the conservative management they will be managed by their Doctor:~1. Bisphosphonates~2. Pain relief~3. Systemic chemotherapy for Myeloma disease~4. Bed rest~5. Radiotherapy~6. Physiotherapy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conservative Management
Description: Patients recruited to Arm 1 and Arm 2 will undergo conservative management for Multiple Myeloma recommended by their Consultant Hematologist.~* Concomitant treatment with bisphosphonates~* Pain relief as required~* Systemic chemotherapy for Myeloma disease~* Bed rest~* Radiotherapy~* Physiotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Management
Description: Patients recruited to Arm 1 and Arm 2 will undergo conservative management for Multiple Myeloma recommended by their Consultant Hematologist.~* Concomitant treatment with bisphosphonates~* Pain relief as required~* Systemic chemotherapy for Myeloma disease~* Bed rest~* Radiotherapy~* Physiotherapy
Study: NCT01554072

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Home based pulmonary rehabilitation with exercise
Description: After each group will receive the randomization their booklets containing the exercise routine that should be performed at home., to be held three times a week for two consecutive months. Is also scheduled a visit to the laboratory biweekly Respiratory Functional Assessment in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based pulmonary rehabilitation with exercise
Description: After each group will receive the randomization their booklets containing the exercise routine that should be performed at home., to be held three times a week for two consecutive months. Is also scheduled a visit to the laboratory biweekly Respiratory Functional Assessment in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused.
Study: NCT02647398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous aerobic training
Description: Supervised vigorous aerobic training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vigorous aerobic training
Description: Supervised vigorous aerobic training
Study: NCT01839929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral
Study: NCT00874861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide vaccine + Poly-ICLC
Description: Subcutaneously in right or left upper arms with intact draining axillary nodes. Each will be injected to the same location in the same arm as the previous vaccine was administered. In case of no intact axillary lymph nodes as draining nodes, vaccines will be administered in the upper thigh on the same side with intact inguinal lymph nodes.~Vaccine will be administered on weeks 0,3,6,9,12,15,18 and 21. Poly-ICLC First course(20 mg/kg i.m., up to 1640 µg/injection) will be administered on an outpatient basis in the Clinical \& Translational Research Center (CTRC)the day of the first GAA/TT-vaccine and on day 4 after the vaccine. For each of the repeated vaccinations (on Weeks 3,6,9,12,15,18 and 21) poly-ICLC will be administered on day of the vaccine and on day 4 after the vaccine.
Study: NCT02835222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study: NCT02835222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV